- Home
- TSSI vs NGEN Comparison
TSSI vs NGEN Comparison
Compare TSSI & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSSI | NGEN |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | Canada |
| Employees | 161 | 9 |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.9M | 314.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TSSI | NGEN |
|---|---|---|
| Price | $11.40 | $3.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $16.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.7M | 162.9K |
| Earning Date | 05-14-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | $42.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.87 | $3.51 |
| 52 Week High | $31.94 | $5.93 |
Technical Indicators
Market Signals| Indicator | TSSI | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.39 | 43.97 |
| Support Level | $7.23 | $3.59 |
| Resistance Level | $13.64 | $4.44 |
| Average True Range (ATR) | 1.29 | 0.20 |
| MACD | -0.60 | -0.00 |
| Stochastic Oscillator | 16.41 | 31.03 |
Price Performance
Historical ComparisonAbout TSSI TSS Inc.
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.